Norway Molecular Diagnostics Market Size & Outlook
Norway molecular diagnostics market, 2018-2030 (US$M)
Related Markets
Norway molecular diagnostics market highlights
- The Norway molecular diagnostics market generated a revenue of USD 87.7 million in 2023 and is expected to reach USD 90.5 million by 2030.
- The Norway market is expected to grow at a CAGR of 0.4% from 2024 to 2030.
- In terms of segment, hospitals was the largest revenue generating end use in 2023.
- Home Care is the most lucrative end use segment registering the fastest growth during the forecast period.
Molecular diagnostics market data book summary
| Market revenue in 2023 | USD 87.7 million |
| Market revenue in 2030 | USD 90.5 million |
| Growth rate | 0.4% (CAGR from 2023 to 2030) |
| Largest segment | Hospitals |
| Fastest growing segment | Home Care |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hospitals, Outpatient Facilities, Home Care |
| Key market players worldwide | Becton Dickinson & Co, BioMerieux SA, Bio-Rad Laboratories Inc, Abbott Laboratories, Agilent Technologies Inc, Danaher Corp, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Roche Holding AG, Siemens Healthineers AG ADR, Sysmex Corp |
Other key industry trends
- In terms of revenue, Norway accounted for 0.2% of the global molecular diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany molecular diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Norway is the fastest growing regional market in Europe and is projected to reach USD 90.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Molecular Diagnostics Market Scope
Molecular Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway molecular diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to molecular diagnostics market will help companies and investors design strategic landscapes.
Hospitals was the largest segment with a revenue share of 46.86% in 2023. Horizon Databook has segmented the Norway molecular diagnostics market based on hospitals, outpatient facilities, home care covering the revenue growth of each sub-segment from 2018 to 2030.
Norway has a high average life expectancy of 82 years. The country's increase in life expectancy over recent years and the consequently large aging population prone to infectious and chronic diseases are expected to support the demand for molecular diagnostics tests. According to the World Life Expectancy in 2020, over 15.6% of total deaths were due to cardiac disorders in the country.
A significant number of older adults are living in Norway, and many are suffering from heart-related problems in the country, which is expected to boost the demand for diagnostics over the coming years. Some of the key players in the Norway market are Gentian Diagnostics ASA, Promega Corporation, and Bio-Techne Corporation.
Reasons to subscribe to Norway molecular diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway molecular diagnostics market databook
-
Our clientele includes a mix of molecular diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Norway molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway molecular diagnostics market size, by end use, 2018-2030 (US$M)
Norway Molecular Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
